Back to TAKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
18 competitors in Multiple Myeloma
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA11/21/2016
Ninlaro
Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Orphan
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
REPLAGALPhase 3
Fabry Disease
Alogliptin and pioglitazonePhase 3
Type 2 Diabetes Mellitus
HYQVIAPhase 3
Primary Immunodeficiency Diseases (PID)
IGSC 20% infusionPhase 3
Primary Immunodeficiency Disease
Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.Phase 3
Hypertension
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts